Safety and Feasibility of Recombinant Factor VIIa for Acute Intracerebral Hemorrhage

Abstract

This small phase II trial evaluated a wide range of rFVIIa doses in acute ICH and raised no major safety concerns. Larger studies are justified to determine whether rFVIIa can safely and effectively limit ICH growth.